Terns Pharmaceuticals (TERN) Total Non-Current Liabilities (2020 - 2023)
Historic Total Non-Current Liabilities for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $12.1 million.
- Terns Pharmaceuticals' Total Non-Current Liabilities rose 4847.86% to $12.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $12.1 million, marking a year-over-year increase of 4847.86%. This contributed to the annual value of $9.0 million for FY2022, which is 2911.17% up from last year.
- Per Terns Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $12.1 million for Q3 2023, which was up 4847.86% from $14.5 million recorded in Q2 2023.
- In the past 5 years, Terns Pharmaceuticals' Total Non-Current Liabilities registered a high of $23.0 million during Q4 2020, and its lowest value of $6.0 million during Q2 2021.
- Over the past 4 years, Terns Pharmaceuticals' median Total Non-Current Liabilities value was $8.4 million (recorded in 2021), while the average stood at $10.2 million.
- In the last 5 years, Terns Pharmaceuticals' Total Non-Current Liabilities plummeted by 6970.62% in 2021 and then surged by 10973.17% in 2023.
- Quarter analysis of 4 years shows Terns Pharmaceuticals' Total Non-Current Liabilities stood at $23.0 million in 2020, then plummeted by 69.71% to $7.0 million in 2021, then increased by 29.11% to $9.0 million in 2022, then surged by 34.82% to $12.1 million in 2023.
- Its last three reported values are $12.1 million in Q3 2023, $14.5 million for Q2 2023, and $12.5 million during Q1 2023.